ZVRA - Zevra Therapeutics: Oversold, Undervalued, and Poised for a Rebound

Key Takeaway: The stock is technically oversold, trading near a 52-week low, and the company’s fundamentals suggest it’s undervalued. The combination of a sharp technical bounce setup and a low valuation could create a short-term trading opportunity for nimble investors.

1. What’s the story in one sentence?

A micro-cap biotech with a thinly-traded stock that’s been beaten down to near 52-week lows, yet whose lead drug candidate is now in Phase 3 and the company has $200 million in cash on hand.

2. Why the stock is down

• The stock is down 45% from its 52-week high after the company announced a delay in its lead drug candidate’s Phase 3 trial.
• The market is overlooking the fact that Zevra has $200 million in cash and a drug with blockbuster potential.

3. What the numbers say

4. The technical setup

• Oversold bounce setup: The stock is oversold on the daily RSI, and the price is sitting right on top of a major support level at $9.82. A bounce from here could target $11.50-$12.00 in the near term.
• Risk/Reward: Downside is limited by the support level at $9.82, while the upside is open to $12.00+ if the technical setup plays out.

5. The fundamentals

• Cash runway: The company has $200 million in cash and no debt, which provides a significant margin of safety.
• Pipeline value: The lead drug candidate has the potential to be a blockbuster if approved, which could justify a much higher valuation.

6. The risks

• The risk: The stock is a micro-cap biotech, so it’s inherently volatile and risky. The trial delay could be a sign of deeper issues.
• The opportunity: If the drug succeeds, the stock could re-rate sharply higher. The cash pile provides downside protection.

7. The trade

• Entry: Buy on any weakness below $10.00, as the stock is oversold and near support.
• Stop-loss: A close below $9.82 would invalidate the setup.
• Target: $11.50-$12.00 in the near term, with the potential for a much larger move if the drug trial results are positive.

8. The bottom line

The stock is oversold and undervalued, and the technical setup is pointing to a potential sharp rebound. The company has a strong balance sheet and a promising drug pipeline. The risk-reward setup is favorable for a short-term trade, with the potential for a significant upside move if the drug trial results are positive.

Disclaimers: This is not financial advice. Investing in micro-cap biotech stocks is inherently risky.